Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

Impact innovation is Sweden's innovation initiative for the 2030s. This week, the first five programs that have been granted funding for the next 10 years were presented, and we are pleased that "Shift2Access" is one of these programs. In 2023, the Flemingsberg Science Foundation initiated discussions with IQ Samhällsbyggnad, which works to make Sweden a leader in sustainable urban development. As a result, in the fall we signed a letter of intent to be included in the "Shift2Access" application, which has now been granted funding.

At the beginning of the year, we had the privilege of welcoming a delegation from England, with representatives from Innovate UK and eleven ATMP (Advanced Therapy Medicinal Products) companies. This marks the beginning of a significant partnership with great potential to ultimately cure diseases that were previously incurable.